ArticlePsychopharmacology2017
A comparative study of QT prolongation with serotonin reuptake inhibitors.
Article in Psychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.Clinical pharmacology and therapeutics · 2023Guideline
- Evidence-Based Pharmacotherapies for Major Depressive Disorder: A Clinical Update.Psychopharmacology bulletin · 2026Review
- Lascufloxacin-Induced QT Prolongation in an Elderly Patient Treated With Escitalopram: A Case Report.Cureus · 2026Article
- An open-label, single-arm, dose-escalating concentration-QT study to investigate the cardiac effects and safety of paroxetine in healthy adults.British journal of clinical pharmacology · 2026Article
- Navigating Anxiety Management in Myasthenia Gravis Crisis With Prolonged Corrected QT (QTc): A Case Report.Cureus · 2026Article
- QT prolongation alerts lead to monitoring but rarely to therapeutic changes: a prospective hospital study.Frontiers in pharmacology · 2026Article
- Case Report: Severe SIADH and QTc prolongation induced by escitalopram-quetiapine interaction in a CYP2C19 intermediate metabolizer at therapeutic doses.Frontiers in pharmacology · 2026Article
- Young patients with congenital heart disease on psychotropic medications have higher recurrence of cardiac events than those without CHD.Frontiers in cardiovascular medicine · 2026Article
- QT interval prolongation: clinical assessment, risk factors and quantitative pharmacological considerations.Journal of pharmacokinetics and pharmacodynamics · 2025Review
- Drug Repositioning in Doxorubicin-Induced Cardiotoxicity Protection.International journal of molecular sciences · 2025Review
- Article
- Serious arrhythmia in initiators of citalopram, escitalopram, and other selective serotonin reuptake inhibitors: A population-based cohort study in older adults.Clinical and translational science · 2022Article
- Chronic Administration of COVID-19 Drugs Fluvoxamine and Lopinavir Shortens Action Potential Duration by Inhibiting the Human Ether-à-go-go-Related Gene and Cav1.2.Frontiers in pharmacology · 2022Article
- Repolarization dispersion in patients with systemic sclerosis.European journal of rheumatology · 2021Article
- Serotonin transporter gene and escitalopram: depressing medical science.European journal of clinical pharmacology · 2020Article
- Prescription of proton pump inhibitors in older adults with complex polytherapy.European journal of hospital pharmacy : science and practice · 2020Article
- PIMD: An Integrative Approach for Drug Repositioning Using Multiple Characterization Fusion.Genomics, proteomics & bioinformatics · 2020Article
- US Common Rule and Informed Consent for Clinical Trials: "Promises only Bind Those Who Believe in Them".Science and engineering ethics · 2020Article
- QT variability index in patients with systemic sclerosis.European journal of rheumatology · 2019Article
- Simplifying QT prolongation for busy clinicians.Canadian family physician Medecin de famille canadien · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundQT interval prolongations were described with citalopram and escitalopram. However, the effects of the other serotonin reuptake inhibitors (SRIs) remained discussed. In order to identify a putative signal with other SRIs, the present study investigates the reports of QT interval prolongation with SRIs in two pharmacovigilance databases (PVDB).
methodsTwo kinds of investigations were performed: (1) a comparative study in VigiBase®, the WHO PVDB, where notifications of QT prolongation with six SRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) were selected. Cases with overdose or pregnancy were excluded. The relationship between the "suspected" SRI and occurrence of QT prolongation was assessed by calculating reporting odds ratio (ROR) in a case/non-case design. (2) A descriptive study of QT prolongation reports with citalopram and escitalopram in the French FPVD.
resultsIn VigiBase®, 855 notifications were identified (mean age 56.2 years, mainly women 73%). Among them, 172 (20.1%) were associated to escitalopram; 299 (35.0%), to citalopram; 186 (21.8%), to fluoxetine; 94 (11.0%), to sertraline; 66 (7.7%), to paroxetine; and 38 (4.4%) to fluvoxamine. A significant ROR value (higher than 1) was only found for citalopram (3.35 CI95% [2.90-3.87]) or escitalopram (2.50 [2.11-2.95]). In the FPVD, eight reports of QT prolongation were found with citalopram and 27 with escitalopram, mainly in women (77.1%) with a mean age of 73.2 years. In 23 cases (66%), SRIs were associated with other suspected drugs, mainly cardiotropic or psychotropic ones. Hypokalemia was associated in six patients.
conclusionThis study, performed in real conditions of life, shows a clear signal of QT prolongation with only two SRIs, citalopram and escitalopram, indicating that QT prolongation is not a SRI class effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.